+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children



Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children



Pediatric Hematology and Oncology 21(2): 115-123



The aim of this study was to evaluate the efficacy and safety of meropenem plus amikacin compared with piperacillin-tazobactam plus netilmicin for initial empirical antibiotic treatment of high-risk febrile neutropenia in children with cancer. Patients with hematologic malignancy (leukemia or stage III/IV non-Hodgkin lymphoma) who presented with fever and neutropenia (ANC < 500/mm3) and patients with solid tumors who presented with fever and severe neutropenia (ANC < 100/mm3) were considered to be at high risk and eligible for this study. In this prospective study, 33 patients with 50 febrile neutropenic episodes received i.v. neropenem (20 mg/kg every 8 h) plus amikacin (15 mg/kg/d in 2 divided doses) (in 31 episodes) or piperacillin/tazobactam (100 mg/4 mg/kg every 8 h) plus netilmicin (7 mg/kg every 24 h) (in 19 episodes). Clinical response was determined at 72 h and at completion of the therapy. The groups were comparable in terms of age, sex, initial ANC, use of growth factors, and classification of the infections. An infection was documented microbiologically in 12 episodes (39%) in the meropenem plus amikacin group and in 8 episodes (42%) in the piperacillin/tazobactam plus netilmicin group. Of the 22 microbiological isolates, 37% were gram-positives, 45% were gram-negatives, and 18% were fungi. Most of the clinically documented infections were of lower respiratory tract, gastrointestinal mucosa, or urinary tract origin. The mean duration of neutropenia was 9 days in both groups. Fever persisted for 1-30 days (mean 3 vs. 5 days). The success rate with initial empiric therapy was 52% in the meropenem plus amikacin and 42% in the piperacillin/tazobactam plus netilmicin group, respectively (p = .5). Total success rate (with or without modification) was 97% vs. 90% in the episodes. Three patients died due to infection (1 vs. 2 patients). No major adverse effects were observed in each group. Empirical therapy with meropenem plus amikacin or piperacillin/tazobactam plus netilmicin for high-risk febrile neutropenia is equally effective and safe in pediatric cancer patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 004231790

Download citation: RISBibTeXText

PMID: 15160510

DOI: 10.1080/08880010490277321


Related references

Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients. Asian Pacific Journal of Cancer Prevention 15(11): 4549-4553, 2014

Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatric Hematology and Oncology 28(4): 311-320, 2011

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clinical Infectious Diseases 33(8): 1295-1301, 2001

A prospective randomized trial comparing the efficacy and safety of piperacillin/tazobactam versus piperacillin/tazobactam plus netilmicin in the treatment of febrile neutropenia in allogeneic stem cell recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 267, 2001

Double-blind, randomized, clinical trial comparing monotherapy with piperacillin-tazobactam vs piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 722, 1999

Randomized comparison of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in children with lymphoma and solid tumors. Pediatric Hematology and Oncology 30(2): 141-148, 2013

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: Results of an open, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 50(1): 79-88, 2002

Cefepime plus amikacin versus piperacillin/tazobactam plus amikacin for initial antibiotic therapy in hematological patients with febrile neutropenia Results of an open, randomized, multicenter trial. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 474, 2000

Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients. Journal of Microbiology Immunology and Infection 51(4): 473-477, 2018

Piperacillin-tazobactam plus netilmicin as empiric treatment for adult patients with acute leukemia, neutropenia, and fever: Single-center experience and retrospective comparison with piperacillin plus netilmicin. Current Therapeutic Research 58(1): 56-69, 1997

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Supportive Care in Cancer 13(6): 387-392, 2005

Imipenem versus piperacillin/tazobactam for empiric treatment of febrile neutropenia in adults. Internal Medicine Journal, 2013

Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination. Medecine et Maladies Infectieuses 35(6): 357-362, 2005

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents & Chemotherapy 39(2): 445-452, 1995

Estimated prescribing costs of piperacillin/tazobactam versus meropenem in the treatment of adult febrile neutropenia. International Journal of Antimicrobial Agents 17(Suppl. 1): S96, 2001